List view / Grid view
A team of scientists from the University of Birmingham has discovered a powerful new treatment for psoriasis. The treatment uses a tripeptide that has shown steroid-level effectiveness in reducing symptoms, offering fresh hope for the long-term management of this chronic skin condition.
What if vaccines could train your immune system to eliminate infections at the source? Find out how Gylden Pharma’s gold nanoparticle platform delivers targeted T cell immunity - providing a precise and durable defence against complex infectious diseases.
Scientists have developed CeSPIACE, a peptide drug that offers broad protection against COVID-19 variants, including Omicron XBB.1.5. Find out how it targets a stable part of the virus’s spike protein, making it resistant to mutations.
A new AI-powered approach is tackling the challenge of 'undruggable' diseases by designing peptides that can bind to and destroy previously untreatable proteins.
A new peptide-based eye drop treatment for dry AMD offers a non-invasive, effective alternative to injectable therapies, enhancing patient convenience and care.
Researchers at the University of Pennsylvania have engineered lipid nanoparticles to target neurons, advancing mRNA treatments for brain diseases.
In lab and fruit fly studies, the new peptide inhibitor effectively acted on both major aggregation-promoting hotspots of Tau proteins.
The findings could aid the design of more stable drugs and improve the understanding of diseases linked to peptide aggregation.
In this Q&A, Pascaline Lécorché, Head of Chemical Biology at Vect-Horus, outlines the potential of RNA interference therapeutics and the challenges of their use in vivo. There are several strategies to overcome these, and why peptide-based vectors targeting the LDL receptor are a promising approach.
In this Q&A, Dr DaeYong Lee discusses how a new method for building up natural immune response could lead to new immunotherapy drugs with safer toxicity profiles.
Researchers have created dual-targeted CARs, which performed better than single-targeted CARs in both in vivo and in vitro experiments.
Scientists demonstrate how disrupting the Cx26 molecular complex in triple-negative breast cancer cells slowed tumour growth.
A novel peptide can suppress MYC by binding directly to it with sub-micro-molar affinity, advancing cancer drug development.
Researchers from Switzerland identify peptides that detect and measure a key biomarker in inflammatory conditions.
Researchers from the University of Illinois have identified a new class of ribosomally synthesised and post-translationally modified peptides (RiPPs) named "daptides" that have haemolytic activity.
